Astorg, a pan-European private equity firm, has announced the completion of two simultaneous transactions: the take-private acquisition of Hamilton Thorne and the purchase of Cook Medical‘s Reproductive Health business (Cook Medical RH). Following these transactions, Hamilton Thorne has been delisted from the Toronto Stock Exchange.
The combined entity will serve customers in over 115 countries, providing fertility clinics and IVF laboratories with a comprehensive portfolio of products. Cook Medical RH brings its portfolio of ART consumables and equipment, including ovum aspiration needles, catheters, and pipettes, while Hamilton Thorne contributes its precision instruments, consumables, software, and services.
“By the joining of forces of Hamilton Thorne and Cook Medical RH we are creating a unique, global, pure-play ART business at scale, with market leadership and an industry-leading product portfolio that is ideally positioned to address rising fertility challenges and better support fertility professionals and families on their fertility journeys,” said Olivier Lieven, Managing Director, Astorg.
To lead the newly combined company, Astorg has appointed Wil Boren as Chief Executive Officer (CEO). Boren brings extensive MedTech sector experience, most recently serving as CEO of Paragon Medical. Jimmy DeStephens joins as Chief Financial Officer (CFO) and Chief Operating Officer (COO), bringing over 20 years of expertise in finance, operations, and business development within the MedTech industry.
The new CEO, Wil Boren, shared: “Today marks a pivotal moment for Hamilton Thorne and Cook Medical RH and I am thrilled to lead the newly combined company, and I look forward to working with both teams joining forces. Hamilton Thorne and Cook Medical RH have impressive reputations, a broad range of innovative and quality-driven products, and outstanding customer service – a testament to the dedication and expertise of both teams. With our combined scope, expertise, and resources, we are uniquely positioned to help IVF clinics and patients, all with the goal of expanding access and improving fertility outcomes worldwide.”
The transaction represents Astorg’s continued investment in healthcare, where it has invested over €6.5 billion. This acquisition will be part of the Astorg VIII portfolio, marking its seventh portfolio company and third healthcare investment. A new brand identity for the combined business is planned for rollout in 2025.
